logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 12611401 B1

PDFFull Text
Date of Patent:
Apr. 28, 2026

Filed:

May. 15, 2020

Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases

Applicant:

Pfizer Inc., New York, NY (US);

Inventors:

Gary E. Aspnes, Biberach an der Riss, DE;

Scott W. Bagley, Mystic, CT (US);

John M. Curto, Mystic, CT (US);

Matthew Dowling, Old Lyme, CT (US);

David James Edmonds, Riehen, CH;

Dilinie Fernando, Jamaica Plain, MA (US);

Mark E. Flanagan, Gales Ferry, CT (US);

Kentaro Futatsugi, Sharon, MA (US);

David Andrew Griffith, Sudbury, MA (US);

Kim Huard, Berkeley, CA (US);

Gajendra Ingle, New Haven, CT (US);

Wenhua Jiao, Salem, CT (US);

Shawn M. Lacasse, Griswold, CT (US);

Yajing Lian, Waterford, CT (US);

Chris Limberakis, Pawcatuck, CT (US);

Allyn T. Londregan, Barrington, RI (US);

Alan M. Mathiowetz, Waltham, MA (US);

David Walter Piotrowski, Waterford, CT (US);

Roger B. Ruggeri, Waterford, CT (US);

Kristin Wiglesworth, Germantown, MD (US);

Assignee:

Pfizer Inc., New York, NY (US);

Attorney:

Hamilton, Brook, Smith & Reynolds, P.C.

Primary Examiner:

Rebecca L Anderson

Int. Cl.
CPC ...
A61K 31/438 (2006.01); A61K 31/454 (2006.01); A61K 31/4545 (2006.01); A61K 31/46 (2006.01); A61K 31/496 (2006.01); A61K 31/506 (2006.01); A61K 31/5377 (2006.01); A61K 38/17 (2006.01); A61K 38/26 (2006.01); A61K 38/28 (2006.01); A61K 45/06 (2006.01); A61P 1/16 (2006.01);
U.S. Cl.
CPC ...
A61K 31/438 (2013.01); A61K 31/454 (2013.01); A61K 31/4545 (2013.01); A61K 31/46 (2013.01); A61K 31/496 (2013.01); A61K 31/506 (2013.01); A61K 31/5377 (2013.01); A61K 38/1709 (2013.01); A61K 38/1796 (2013.01); A61K 38/26 (2013.01); A61K 38/28 (2013.01); A61K 45/06 (2013.01); A61P 1/16 (2018.01);
Abstract

In part, the invention provides a new combination comprising (1) a GLP-1R agonist and (2) an ACC inhibitor or a DGAT2 inhibitor, or a KHK inhibitor or FXR agonist. The invention further provides new methods for treating diseases and disorders, for example, fatty liver, nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, nonalcoholic steatohepatitis with liver fibrosis, nonalcoholic steatohepatitis with cirrhosis, and nonalcoholic steatohepatitis with cirrhosis and with hepatocellular carcinoma or with a metabolic-related disease, obesity, and type 2 diabetes, for example, using the new combination described herein.

Find Patent Forward Citations

Loading…